Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Ophthalmology

Treatment Options and Decision Tree for LSCD

At a Glance

Treatment for Limbal Stem Cell Deficiency (LSCD) begins with medical management like intensive eye drops and scleral lenses to stabilize the eye. If surgery is needed, doctors use your own healthy cells for unilateral LSCD to avoid rejection, or donor tissue with anti-rejection drugs for bilateral LSCD.

Treating Limbal Stem Cell Deficiency (LSCD) is a step-by-step process. Before considering major surgery, your care team will focus on stabilizing the surface of your eye and “calming the fire” of any active inflammation [1][2].

Foundation: Medical Management

For many patients, especially those with partial LSCD, medical management is the first and most important step. These treatments aim to support the remaining stem cells and improve comfort [3][4].

  • Intensive Lubrication: Using preservative-free artificial tears and ointments to keep the surface moist [5].
  • Autologous Serum Tears: Eye drops made from your own blood, which contain natural growth factors that help heal the eye surface [6][7].
  • Scleral Lenses: Specialized, large-diameter contact lenses that rest on the white of the eye and create a “vault” of fluid over the cornea, providing constant hydration and protection [8].
  • Anti-Inflammatory Therapy: Using steroid or other immune-modulating drops to reduce the chronic inflammation that often kills off stem cells [1].

Choosing the Right Surgery

If medical management is not enough to restore vision or comfort, surgery may be necessary. The choice of surgery depends entirely on whether your condition is in one eye (unilateral) or both eyes (bilateral) [9].

Option A: Unilateral LSCD (Autografts)

In these cases, your other eye is healthy. This is the “gold standard” because the doctor can use your own cells, meaning there is no risk of rejection and no need for long-term anti-rejection drugs [10][11].

  • SLET (Simple Limbal Epithelial Transplantation): The surgeon takes a tiny piece of tissue from your healthy eye, divides it into small “seeds,” and places them on the sick eye [12]. This is often preferred because it is cost-effective and requires very little donor tissue [13][14].
  • CLAU (Conjunctival-Limbal Autograft): A larger piece of tissue (including the conjunctiva) is moved from the healthy eye to the sick eye [15].
  • CLET (Cultivated Limbal Epithelial Transplantation): A small sample is taken and grown in a laboratory for several weeks before being transplanted back to you [16].

Option B: Bilateral LSCD (Allografts)

When both eyes are affected, there is no “healthy eye” to borrow from. Doctors must use tissue from a donor [17].

  • KLAL (Keratolimbal Allograft): Large pieces of limbal tissue from a deceased donor are transplanted onto your eye [18].
  • Allogeneic SLET/CLET: Similar to the autograft techniques above, but using cells from a living relative or a deceased donor [19][20].
  • The Trade-off: Because these cells come from someone else, you must take systemic immunosuppression (anti-rejection medication) to prevent your body from attacking the new cells [21][22].

What to Expect: Recovery Timeline

Recovery from these surgeries is a gradual process. It can take several months for the surface to heal completely and for your vision to fully stabilize [23]. The initial weeks involve intensive eye drops and monitoring to ensure the transplanted cells are successfully taking hold.

Decision Tree Summary

Situation Recommended Source Common Procedure Key Requirement
One Eye Affected Your Healthy Eye (Autograft) SLET, CLAU Healthy fellow eye [9]
Both Eyes Affected Donor or Relative (Allograft) KLAL, Allo-SLET Systemic Immunosuppression [21]
Both Eyes (Avoiding Immunosuppression) Your Mouth (COMET) Oral Mucosa No rejection drugs needed [24]

Note: COMET (Cultivated Oral Mucosal Epithelial Transplantation) uses cells from the inside of your cheek. While it doesn’t restore a perfect corneal surface, it can provide stability for patients who cannot tolerate donor tissue or rejection drugs [24][25].

Common questions in this guide

How is Limbal Stem Cell Deficiency treated without surgery?
Initial treatment for LSCD focuses on stabilizing the eye surface and reducing inflammation without surgery. This often includes using preservative-free artificial tears, autologous serum tears made from your own blood, scleral contact lenses, and anti-inflammatory eye drops.
Does LSCD surgery require cells from a donor?
If you have unilateral LSCD in just one eye, surgeons can use your own healthy stem cells from your other eye, meaning there is no risk of rejection. For bilateral LSCD where both eyes are affected, donor tissue is required, which usually means taking immunosuppressant medication.
Will I need to take anti-rejection medication after LSCD surgery?
You will generally only need to take systemic anti-rejection medications if your surgery uses tissue from a deceased donor or a living relative. Surgeries that use your own cells, such as an autograft from a healthy eye or tissue from inside your cheek, do not require these medications.
What is SLET eye surgery?
Simple Limbal Epithelial Transplantation (SLET) is a cost-effective surgery where a doctor takes a tiny piece of tissue from your healthy eye. The tissue is divided into small seeds and placed on your sick eye to help it regenerate a healthy surface.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my LSCD currently stable enough for surgery, or do we need to focus more on medical management first?
  2. 2.Given that I have unilateral/bilateral LSCD, which specific surgical technique do you recommend for me?
  3. 3.If we use a donor (allograft), what will my immunosuppression regimen look like, and what are the systemic risks?
  4. 4.Are there any living relatives who could act as a donor to reduce my risk of rejection?
  5. 5.If we choose a transplant, what is the expected timeline for recovery and visual improvement?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Evaluation of Medically Reversible Limbal Stem Cell Deficiency.

    Korkmaz İ, Eratılgan NF, Palamar M, et al.

    Turkish journal of ophthalmology 2024; (54(5)):251-256 doi:10.4274/tjo.galenos.2024.69705.

    PMID: 39463138
  2. 2

    Case Report: Simultaneous penetrating keratoplasty with autologous simple limbal epithelial transplantation as an alternative to keratoprosthesis.

    Sharma S, Singh S, Shanbhag SS

    F1000Research 2023; (12()):488 doi:10.12688/f1000research.133637.3.

    PMID: 37455854
  3. 3

    [Long-term results of autologous transplantation of limbal epithelium cultivated ex vivo for limbal stem cell deficiency].

    Scholz SL, Thomasen H, Hestermann K, et al.

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2016; (113(4)):321-9 doi:10.1007/s00347-015-0110-y.

    PMID: 26271737
  4. 4

    Existence of Normal Limbal Epithelium in Eyes With Clinical Signs of Total Limbal Stem Cell Deficiency.

    Chan E, Le Q, Codriansky A, et al.

    Cornea 2016; (35(11)):1483-1487 doi:10.1097/ICO.0000000000000914.

    PMID: 27362882
  5. 5

    Ocular toxicity of mustard gas: A concise review.

    Fuchs A, Giuliano EA, Sinha NR, Mohan RR

    Toxicology letters 2021; (343()):21-27 doi:10.1016/j.toxlet.2021.02.007.

    PMID: 33600921
  6. 6

    The role of limbal stem cells on neurotrophic cornea.

    Ciftci MD, Dereli Can G, Gurdal M, Barut Selver O

    Clinical & experimental optometry 2025; 1-7 doi:10.1080/08164622.2025.2561862.

    PMID: 40975896
  7. 7

    Current and Emerging Therapies for Limbal Stem Cell Deficiency.

    Elhusseiny AM, Soleimani M, Eleiwa TK, et al.

    Stem cells translational medicine 2022; (11(3)):259-268 doi:10.1093/stcltm/szab028.

    PMID: 35303110
  8. 8

    Allogeneic simple limbal epithelial transplantation for bilateral limbal stem cell deficiency in chronic vernal keratoconjunctivitis: A case report.

    Jain N, Kate A, Chaudhary S, Basu S

    International journal of surgery case reports 2022; (94()):106968 doi:10.1016/j.ijscr.2022.106968.

    PMID: 35427890
  9. 9

    Surgical Management of Limbal Stem Cell Deficiency.

    Iyer G, Srinivasan B, Agarwal S, et al.

    Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; (9(6)):512-523 doi:10.1097/APO.0000000000000326.

    PMID: 33323706
  10. 10

    Limbal stem cell transplantation: current perspectives.

    Atallah MR, Palioura S, Perez VL, Amescua G

    Clinical ophthalmology (Auckland, N.Z.) 2016; (10()):593-602 doi:10.2147/OPTH.S83676.

    PMID: 27099468
  11. 11

    Long-Term Results of Cultured Limbal Stem Cell Versus Limbal Tissue Transplantation in Stage III Limbal Deficiency.

    Borderie VM, Ghoubay D, Georgeon C, et al.

    Stem cells translational medicine 2019; (8(12)):1230-1241 doi:10.1002/sctm.19-0021.

    PMID: 31486585
  12. 12

    Economic, clinical and social impact of simple limbal epithelial transplantation for limbal stem cell deficiency.

    Thokala P, Singh A, Singh VK, et al.

    The British journal of ophthalmology 2022; (106(7)):923-928 doi:10.1136/bjophthalmol-2020-318642.

    PMID: 33688000
  13. 13

    Simple limbal epithelial transplantation (SLET) in failed cultivated limbal epithelial transplantation (CLET) for unilateral chronic ocular burns.

    Basu S, Mohan S, Bhalekar S, et al.

    The British journal of ophthalmology 2018; (102(12)):1640-1645 doi:10.1136/bjophthalmol-2017-311506.

    PMID: 29453224
  14. 14

    Simple limbal epithelial transplantation: a review on current approach and future directions.

    Borroni D, Wowra B, Romano V, et al.

    Survey of ophthalmology 2018; (63(6)):869-874 doi:10.1016/j.survophthal.2018.05.003.

    PMID: 29800578
  15. 15

    Conjunctival-limbal autograft.

    Daya SM

    Current opinion in ophthalmology 2017; (28(4)):370-376 doi:10.1097/ICU.0000000000000385.

    PMID: 28399069
  16. 16

    Autologous limbal stem cell transplantation: a systematic review of clinical outcomes with different surgical techniques.

    Shanbhag SS, Nikpoor N, Rao Donthineni P, et al.

    The British journal of ophthalmology 2020; (104(2)):247-253 doi:10.1136/bjophthalmol-2019-314081.

    PMID: 31118185
  17. 17

    [Research progress on limbal stem cell transplantation].

    Wang LY, Liang QF

    [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 2020; (56(12)):956-960 doi:10.3760/cma.j.cn112142-20201022-00526.

    PMID: 33342123
  18. 18

    Outcome of keratolimbal allograft transplantation with deep anterior lamellar keratoplasty for bilateral limbal stem cell deficiency.

    Li Z, Yang K, Zhou Y, et al.

    Frontiers in medicine 2022; (9()):986194 doi:10.3389/fmed.2022.986194.

    PMID: 36457564
  19. 19

    Limbal Stem Cell Transplantation and Complications.

    Yin J, Jurkunas U

    Seminars in ophthalmology 2018; (33(1)):134-141 doi:10.1080/08820538.2017.1353834.

    PMID: 29172876
  20. 20

    En Bloc Keratolimbal Allograft and Central Penetrating Keratoplasty: A Novel Surgical Technique in Severe Limbal Stem Cell Deficiency.

    Karimian F, Hassanpour K

    Cornea 2023; (42(5)):656-661 doi:10.1097/ICO.0000000000003199.

    PMID: 36729670
  21. 21

    Outcomes of keratolimbal allograft from ABO compatible donors for severe bilateral limbal stem cell deficiency.

    Mimouni M, Cole E, Kim SJ, et al.

    The ocular surface 2023; (27()):48-53 doi:10.1016/j.jtos.2022.11.002.

    PMID: 36371055
  22. 22

    Topical Tacrolimus Compared With Oral Tacrolimus for Postoperative Immunosuppression in Primary Keratolimbal Allograft.

    Tran TM, Azher TN, Miller CJ, Hou JH

    Cornea 2024; (43(3)):333-342 doi:10.1097/ICO.0000000000003316.

    PMID: 37267473
  23. 23

    Multi-parametric evaluation of autologous cultivated Limbal epithelial cell transplantation outcomes of Limbal stem cell deficiency due to chemical burn.

    Selver OB, Gurdal M, Yagci A, et al.

    BMC ophthalmology 2020; (20(1)):325 doi:10.1186/s12886-020-01588-6.

    PMID: 32762738
  24. 24

    Labial mucosal epithelium grafting in an ex vivo human donor cornea model.

    Gerasimov MY, Ostrovskiy DS, Shatskikh AV, et al.

    Experimental eye research 2022; (216()):108931 doi:10.1016/j.exer.2022.108931.

    PMID: 35063476
  25. 25

    Comparison of the efficacy of different cell sources for transplantation in total limbal stem cell deficiency.

    Wang J, Qi X, Dong Y, et al.

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2019; (257(6)):1253-1263 doi:10.1007/s00417-019-04316-z.

    PMID: 31004182

This page provides educational information about LSCD treatment and surgical options. Always consult your ophthalmologist or cornea specialist to determine the safest and most effective treatment plan for your specific condition.

Get notified when new evidence is published on Limbal stem cell deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.